Clinical trials
Endometrial Neoplasms trials in Austria
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
25 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2002 | 1 |
| 2007 | 1 |
| 2011 | 2 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 1 |
| 2023 | 2 |
| 2025 | 5 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 12 |
| Recruiting | 6 |
| Active, not recruiting | 3 |
| Unknown status | 3 |
| Suspended | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| European Organisation for Research and Treatment of Cancer - EORTC | 4 |
| Merck Sharp & Dohme LLC | 4 |
| AstraZeneca | 3 |
| Medical University Innsbruck | 2 |
| AEterna Zentaris | 1 |
| Amgen | 1 |
| BioNTech SE | 1 |
| Clovis Oncology, Inc. | 1 |
| Eikon Therapeutics | 1 |
| Kartos Therapeutics, Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Endometrial Neoplasms | 25 |
| Uterine Cervical Neoplasms | 5 |
| Ovarian Neoplasms | 4 |
| Neoplasms | 3 |
| Breast Neoplasms | 2 |
| Colorectal Neoplasms | 2 |
| Kidney Neoplasms | 2 |
| Lung Neoplasms | 2 |
| Neoplasm Metastasis | 2 |
| Pancreatic Neoplasms | 2 |
Trials
Showing 76 to 25 of 25. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.